Eli Lilly and Company’s stock price fell after an unsolicited “mini-tender” offer by Tutanota LLC, potentially impacting its short-term performance.
Stock AI’s forecasts:
🔴 -3.0% short-term ⬇️
🟢 +1.2% long-term ⬆️
Stock AI’s (LLY) Forecast get (+6.5% Profit)
StockAI’s analysis delivers real-world results. On 11 April 2024, $LLY ($753.8), StockAI predicted a long-term 🟢 buy signal. It was accurate: 1 month later price increased to $803.1 (🟢6.5%). Buying LLY on this signal yielded a +6.5% profit 💰💰.
LLY-Eli Lilly and Company News
🔴 Eli Lilly and Company has been notified of an unsolicited “mini-tender” offer by Tutanota LLC to purchase shares.
🟢 Cannell & Co. increased its stake in Eli Lilly and Company by 65.9% in the 4th quarter.
🔴 International Assets Investment Management LLC raised its position in shares of Eli Lilly and Company by 5.3% in the 4th quarter.
🟢 Providence First Trust Co bought a new position in shares of Eli Lilly and Company during the fourth quarter.
🔴 Wedge Capital Management L L P NC reduced its position in Eli Lilly and Company by 3.3% in the fourth quarter.
🟢 Eli Lilly shares target raised on Zepbound sales potential.
Eli Lilly and Company has been facing a mix of positive and negative news recently, impacting its stock price. The unsolicited “mini-tender” offer from Tutanota LLC has raised concerns among shareholders, leading to a slight decline in the stock price. However, increased stakes from Cannell & Co. and International Assets Investment Management LLC have boosted investor confidence, resulting in a rise in the stock price.
On the other hand, the new position from Providence First Trust Co has added some uncertainty to the stock, causing a slight drop in price. Additionally, the reduction in position by Wedge Capital Management L L P NC has had a negative impact on the stock price.
Overall, the combination of these factors has created a mixed outlook for Eli Lilly and Company stock, with both positive and negative influences affecting the price. Investors will need to closely monitor these developments to make informed decisions about their investments in the company.
LLY-Eli Lilly and Company Analyst Ratings
📉 Leerink Partnrs lowered their Q2 2024 earnings per share estimates for Eli Lilly and Company in a research note issued on Wednesday, May 1st.
📈 Zacks Research analysts raised their Q2 2024 earnings per share estimates for Eli Lilly and Company in a research note issued on Thursday, May 16th.
📈 Argus raised their price target on Eli Lilly and Company stock from $770.00 to $840.00.
Sources:
1. ETF Daily News
2. ETF Daily News
3. ETF Daily News
4. ETF Daily News
5. ETF Daily News
Disclaimer
Investors may consider the AI predictions and news summaries as one factor in their investment decisions alongside their own research and risk tolerance.
Ready to analyze your own portfolio?
Get the same AI-powered insights for any stock you choose. It's easy!
